Evidence map›Paper›PMID 25419179›Full record

Trial reportBMC anesthesiology2014

Study protocol of a randomised controlled trial comparing perioperative intravenous insulin, GIK or GLP-1 treatment in diabetes-PILGRIM trial.

Jorinde A W Polderman, Peter L Houweling, Markus W Hollmann, J Hans DeVries, Benedikt Preckel, Jeroen Hermanides

Registry-linked trialOpen access · goldFull text readComparative StudyMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in BMC anesthesiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT02036372. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02036372 nacompleted

PILGRIM - Perioperative Insulin, GIK or GLP-1 Treatment in Diabetes Mellitus Type II

Ran2014Enrolled150Registered outcomes7Posted comparisons0ConditionsDiabetes Mellitus Type IIArmsGIK infusion, Insulin bolus, liraglutide
Open the trial in the graph
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Liraglutide as an Alternative to Insulin for Glycemic Control in Intensive Care Unit: A Randomized, Open-label, Clinical Study.Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Jorinde A W PoldermanDepartment of Anaesthesiology, Academic Medical Centre, Amsterdam, the Netherlands, Postbus 22660, 1100 DD Amsterdam, the Netherlands.
Peter L HouwelingDepartment of Anaesthesiology, Diakonessenhuis, Utrecht, the Netherlands, Bosboomstraat 1, 3582 KE Utrecht, the Netherlands.
Markus W HollmannDepartment of Anaesthesiology, Academic Medical Centre, Amsterdam, the Netherlands, Postbus 22660, 1100 DD Amsterdam, the Netherlands.
J Hans DeVriesDepartment of Internal Medicine, Academic Medical Centre, Amsterdam, the Netherlands, Postbus 22660, 1100 DD Amsterdam, the Netherlands.
Benedikt PreckelDepartment of Anaesthesiology, Academic Medical Centre, Amsterdam, the Netherlands, Postbus 22660, 1100 DD Amsterdam, the Netherlands.
Jeroen HermanidesDepartment of Anaesthesiology, Academic Medical Centre, Amsterdam, the Netherlands, Postbus 22660, 1100 DD Amsterdam, the Netherlands.
Academic Medical Center · NLUniversity of Amsterdam · NLDiakonessenhuis hospital · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDiabetes mellitus (DM) is associated with poor outcome after surgery. The prevalence of DM in hospitalised patients is up to 40%, meaning that the anaesthesiologist will encounter a patient with DM in the operating room on a daily basis. Despite an abundance of published glucose lowering protocols and the known negative outcomes associated with perioperative hyperglycaemia in DM, there is no evidence regarding the optimal intraoperative glucose lowering treatment. In addition, protocol adherence is usually low and protocol targets are not simply met. Recently, incretins have been introduced to lower blood glucose. The main hormone of the incretin system is glucagon-like peptide-1 (GLP-1). GLP-1 increases insulin and decreases glucagon secretion in a glucose-dependent manner, resulting in glucose lowering action with a low incidence of hypoglycaemia. We set out to determine the optimal intraoperative treatment algorithm to lower glucose in patients with DM type 2 undergoing non-cardiac surgery, comparing intraoperative glucose-insulin-potassium infusion (GIK), insulin bolus regimen (BR) and GPL-1 (liragludite, LG) treatment. METHODS/

designThis is a multicentre randomised open label trial in patients with DM type 2 undergoing non-cardiac surgery. Patients are randomly assigned to one of three study arms; intraoperative glucose-insulin-potassium infusion (GIK), intraoperative sliding-scale insulin boluses (BR) or GPL-1 pre-treatment with liraglutide (LG). Capillary glucose will be measured every hour. If necessary, in all study arms glucose will be adjusted with an intravenous bolus of insulin. Researchers, care givers and patients will not be blinded for the assigned treatment. The main outcome measure is the difference in median glucose between the three study arms at 1 hour postoperatively. We will include 315 patients, which gives us a 90% power to detect a 1 mmol l(-1) difference in glucose between the study arms. DISCUSSION: The PILGRIM trial started in January 2014 and will provide relevant information on the perioperative use of GLP-1 agonists and the optimal intraoperative treatment algorithm in patients with diabetes mellitus type 2.

trial registrationClinicalTrials.gov, NCT02036372.

Indexed as

AlgorithmsBlood GlucoseDiabetes Mellitus, Type 2Glucagon-Like Peptide 1GlucoseHumansHypoglycemic AgentsInfusions, IntravenousInsulinLiraglutidePerioperative CarePostoperative ComplicationsPotassiumResearch DesignSurgical Procedures, OperativeBlood GlucoseGlucagon-Like Peptide 1Glucoseglucose-insulin-potassium cardioplegic solutionHypoglycemic AgentsInsulinLiraglutidePotassiumDiabetes mellitus type 2GLP-1 agonistPerioperative management

Identifiers

PMID25419179
PMCPMC4240889
OpenAlexW2089144165

What OpenQuestion holds

Textfull text, public
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.